CytomX Therapeutics, Inc. (CTMX) Stock Analysis and Metrics

CytomX Therapeutics

NASDAQ: CTMX

$3.24 ▼ -0.09 (-2.56%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap574.36 Mn

P/E-10.39

P/S16.16

Div. Yield0.00

Revenue Growth (1y) (Qtr)-79.85

Add ratio to table…

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet needs in cancer. The company leverages its PROBODY technology platform to create conditionally activated, masked biologics designed to selectively target tumors while minimizing toxicity in healthy tissues. Its core activities involve research, development, and clinical testing of therapeutic candidates across multiple modalities, including antibody-drug conjugates, T-cell engagers, and cytokines.

CytomX generates revenue primarily through strategic collaborations with major biopharmaceutical companies, which include upfront payments, milestone payments, and potential future royalties. The company has entered into alliances with Amgen, Astellas, Bristol Myers Squibb, Moderna, and Regeneron to advance its pipeline of PROBODY therapeutics. These partnerships provide funding for preclinical and clinical development, as well as access to additional resources and expertise. Revenue is derived from the achievement of development, regulatory, and commercial milestones under these agreements.

The company operates through the following segments:

• PROBODY Antibody-Drug Conjugates: This segment focuses on the development of conditionally activated ADCs such as Varseta-M, which targets EpCAM and is armed with a topoisomerase-1 inhibitor payload. Varseta-M is designed to optimize the therapeutic index for EpCAM-expressing cancers, including colorectal cancer. The payload-antibody linker is engineered to drive bystander killing of neighboring tumor cells.

• PROBODY Cytokines: This segment includes CX-801, a dually-masked, conditionally activated version of interferon alpha-2b designed to be preferentially active in the tumor microenvironment. CX-801 leverages a peptide mask and an Fc steric mask to limit systemic activity and extend half-life. The program is currently in Phase 1 development for advanced melanoma, both as monotherapy and in combination with KEYTRUDA®.

• PROBODY T-Cell Engagers: This segment encompasses preclinical programs such as CX-908, a dually-masked PROBODY TCE targeting CDH3 and CD3, developed in collaboration with Amgen. The segment also includes ongoing TCE efforts with Bristol Myers Squibb and Regeneron. These therapies are designed to widen the therapeutic window by reducing cytokine release and improving tolerability compared to unmasked counterparts.

CytomX holds a pioneering position in the field of conditionally activated biologics through its PROBODY technology platform, which enables selective tumor targeting and improved therapeutic index. The company faces competition from entities such as AbbVie, Amgen, Bristol Myers Squibb, Merck, Roche, and Takeda in the ADC, TCE, and immunotherapy spaces. Its competitive advantages stem from over 15 years of PROBODY platform expertise, a strong intellectual property portfolio with at least 245 granted patents and 300 pending applications, and deep knowledge of tumor-associated proteases. The versatility of the platform across modalities allows CytomX to address targets that are limited by toxicity in healthy tissues, such as EpCAM and interferon alpha-2b.

CytomX serves patients with advanced solid tumors, particularly those with colorectal cancer and melanoma, who have exhausted standard treatment options. The company's clinical programs focus on late-line metastatic colorectal cancer and advanced melanoma, where treatment alternatives are limited. Its therapeutic candidates are intended for use in combination with existing therapies such as bevacizumab and KEYTRUDA® to improve outcomes in difficult-to-treat populations.

Investment Thesis

▲ Bull case

CytomX is positioned to capture a significant portion of the growing late-line colorectal cancer market through Varseta-M, a first-in-class EpCAM-targeting antibody drug conjugate that has demonstrated differentiated efficacy with a 32% confirmed overall response rate and median progression-free survival of 7.1 months at the 10 mg/kg dose level in late-line patients heavily pretreated with a median of four prior lines of therapy, addressing a critical unmet need where current standard of care delivers objective response rates in the low single digits and progression-free survival of only 2 to 5 months, and with projected addressable patients in the U.S. alone reaching 45,000 by 2040, the opportunity represents a multibillion-dollar potential even before considering earlier-line expansion or pan-tumor applications. The company has made substantial progress in mitigating the historical toxicity barrier that has prevented EpCAM targeting, with dose optimization incorporating adjusted ideal body weight dosing and mandatory dual prophylaxis with loperamide and budesonide reducing grade 3 diarrhea from 29% in the expansion cohorts to 10% in early optimization data, a meaningful improvement that supports the potential for Varseta-M to move into earlier lines of therapy where chemotherapy regimens already induce gastrointestinal toxicity, making prophylactic agents like loperamide and budesonide clinically familiar and easier to integrate into real-world practice without adding significant burden. CytomX’s strategy to advance Varseta-M into earlier lines of colorectal cancer, including combination with bevacizumab and chemotherapy, leverages the drug’s activity across KRAS wild-type and mutant tumors and microsatellite stable disease—populations that represent the majority of colorectal cancer patients—and its lack of requirement for biomarker selection allows for rapid uptake in community oncology settings, where complex testing delays treatment initiation, positioning Varseta-M as a potential replacement for irinotecan-based regimens and opening a much larger market opportunity beyond the current late-line focus. The PROBODY platform’s ability to unlock EpCAM as a target—previously deemed undruggable due to widespread expression in normal tissues—provides a durable competitive moat, as evidenced by the absence of classic EpCAM toxicities such as pancreatitis and severe liver toxicity in clinical data, and the platform’s applicability to other EpCAM-positive solid tumors like gastric, pancreatic, lung, ovarian, and breast cancers creates a multi-product pipeline opportunity where CytomX can leverage its validated technology to pursue additional indications after establishing proof of concept in colorectal cancer, a disease historically resistant to innovation. Management’s focus on overall survival as the primary endpoint for the planned registrational study, despite impressive progression-free survival data, reflects a disciplined approach to regulatory and payer engagement, increasing the likelihood of favorable label acceptance and premium pricing potential, while the anticipated rapid enrollment in pivotal trials—supported by high investigator interest and the drug’s activity in heavily pretreated patients—suggests a de-risked path to first approval in the first half of 2027, with subsequent data readouts expected to catalyze re-rating of the stock as clinical and commercial milestones are achieved.

CytomX is positioned to capture a significant portion of the growing late-line colorectal cancer market through Varseta-M, a first-in-class EpCAM-targeting antibody drug conjugate that has demonstrated differentiated efficacy with a 32% confirmed overall response rate and median progression-free survival of 7.1 months at the 10 mg/kg dose level in late-line patients heavily pretreated with a median of four prior lines of therapy, addressing a critical unmet need where current standard of care delivers objective response rates in the low single digits and progression-free survival of only 2 to 5 months, and with projected addressable patients in the U.S. alone reaching 45,000 by 2040, the opportunity represents a multibillion-dollar potential even before considering earlier-line expansion or pan-tumor applications. The company has made substantial progress in mitigating the historical toxicity barrier that has prevented EpCAM targeting, with dose optimization incorporating adjusted ideal body weight dosing and mandatory dual prophylaxis with loperamide and budesonide reducing grade 3 diarrhea from 29% in the expansion cohorts to 10% in early optimization data, a meaningful improvement that supports the potential for Varseta-M to move into earlier lines of therapy where chemotherapy regimens already induce gastrointestinal toxicity, making prophylactic agents like loperamide and budesonide clinically familiar and easier to integrate into real-world practice without adding significant burden. CytomX’s strategy to advance Varseta-M into earlier lines of colorectal cancer, including combination with bevacizumab and chemotherapy, leverages the drug’s activity across KRAS wild-type and mutant tumors and microsatellite stable disease—populations that represent the majority of colorectal cancer patients—and its lack of requirement for biomarker selection allows for rapid uptake in community oncology settings, where complex testing delays treatment initiation, positioning Varseta-M as a potential replacement for irinotecan-based regimens and opening a much larger market opportunity beyond the current late-line focus. The PROBODY platform’s ability to unlock EpCAM as a target—previously deemed undruggable due to widespread expression in normal tissues—provides a durable competitive moat, as evidenced by the absence of classic EpCAM toxicities such as pancreatitis and severe liver toxicity in clinical data, and the platform’s applicability to other EpCAM-positive solid tumors like gastric, pancreatic, lung, ovarian, and breast cancers creates a multi-product pipeline opportunity where CytomX can leverage its validated technology to pursue additional indications after establishing proof of concept in colorectal cancer, a disease historically resistant to innovation. Management’s focus on overall survival as the primary endpoint for the planned registrational study, despite impressive progression-free survival data, reflects a disciplined approach to regulatory and payer engagement, increasing the likelihood of favorable label acceptance and premium pricing potential, while the anticipated rapid enrollment in pivotal trials—supported by high investigator interest and the drug’s activity in heavily pretreated patients—suggests a de-risked path to first approval in the first half of 2027, with subsequent data readouts expected to catalyze re-rating of the stock as clinical and commercial milestones are achieved.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password